Effects of prostaglandins on the aqueous humor outflow pathways

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages

  Weinreb, Robert N ^a   Toris, Carol B ^b   Gabelt, B'Ann T ^c   Lindsey, James D ^a   Kaufman, Paul L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Ciliary muscle; Collagen; Extracellular matrix; Matrix metalloproteinase; Prostaglandin; Trabecular outflow facility; Uveoscleral outflow

Indexed keywords

CELL SURFACE RECEPTOR; MATRIX METALLOPROTEINASE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT;

AQUEOUS HUMOR OUTFLOW; CELL SHAPE; CILIARY MUSCLE; DRUG EFFECT; DRUG MECHANISM; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; INTRAOCULAR PRESSURE; IRIS; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCLERA; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; TRANSCRIPTION REGULATION;

EID: 0036669531     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00306-5     Document Type: Article

References (102)

1. Abramovitz M., Boie Y., Nguyen T.et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 269:1994;2632-2636.
2. Alm A., Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 109:1991;1564-1568.
3. Anthony T., Pierce K., Stamer W., Regan J. Prostaglandin F2 receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 39:1998;315-321.
4. Bárány E. Simultaneous measurement of changing the intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest Ophthalmol Vis Sci. 3:1964;135-143.
5. Bárány E, Rohen J: Localized contraction and relaxation within the ciliary muscle of the vervet monkey Cercopithecus ethiops, in The Structure of the Eye. II. Symposium. Stuttgart: F. K. Schattauer-Verlag, 1965, pp 287-311
6. Benbow U., Brinckerhoff C.E. The AP-1 site and MMP gene regulation. what is all the fuss about? Matrix Biol. 15:1997;519-526.
7. Berg A., Ekwall A.K., Rubin K.et al. Effect of PGE1, PGI2, and PGF2 alpha analogs on collagen gel compaction in vitro and interstitial pressure in vivo. Am J Physiol. 274:1998;H663-H671.
8. Bill A. Uveoscleral drainage of aqueous humor. physiology and pharmacology Prog Clin Biol Res. 312:1989;417-427.
9. Bill A. Blood circulation and fluid dynamics in the eye. Physiol Rev. 55:1975;383-417.
10. Bill A. Effects of longstanding stepwise increments in eye pressure on the rate of aqueous humor formation in a primate (Cercopithecus ethiops). Exp Eye Res. 12:1971;184-193.
11. Bill A. Effects of atropine and pilocarpine on aqueous humour dynamics in cynomolgus monkeys (Macaca irus). Exp Eye Res. 6:1967;120-125.
12. Bill A. Conventional and uveo-scleral drainage of aqueous humour in the cynomolgus monkey (Macaca irus) at normal and high intraocular pressures. Exp Eye Res. 5:1966;45-54.
13. Bill A. Aspects of the drainage of aqueous humor in cats. Arch Ophthalmol. 67:1962;148-155.
14. Camras C: Safety and side-effects of latanoprost, in Weinreb R, Kitazawa Y, Krieglstein G (eds): Glaucoma in the 21st Century. London: Mosby International Ltd, 2000, pp 201-11
15. Camras C.B., Siebold E.C., Lustgarten J.S.et al. Maintained reduction of intraocular pressure by prostaglandin F2 alpha- 1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 96:1989;1329-1336. discussion 1336-7.
16. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors. properties, distribution, and structure of the receptors and their subtypes Pharmacol Rev. 46:1994;205-229.
17. Crawford K., Kaufman P., Hubbard W., Woodward D. The DP-receptor agonist SQ27986 raises but does not lower intraocular pressure in ocular normotensive monkeys. J Glaucoma. 1:1992;94-99.
18. Crawford K., Kaufman P.L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 105:1987;1112-1116.
19. Crawford K., Kaufman P.L., Gabelt B.T. Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 6:1987;1035-1044.
20. Crawford K.S., Kaufman P.L. Dose-related effects of prostaglandin F2-isopropyl ester on intraocular pressure, refraction and pupil diameter in monkeys. Invest Ophthalmol Vis Sci. 32:1991;510-519.
21. Fujino H., Srinivasan D., Pierce K.L., Regan J.W. Differential regulation of prostaglandin F. 2-receptor(isoforms by protein kinase C Mol Pharmacol 57):2000;353-358.
22. Funck R.C., Wilke A., Rupp H., Brilla C.G. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol. 432:1997;35-44.
23. Gabelt B.T., Kaufman P.L. The effect of prostaglandin F2 alpha on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res. 51:1990;87-91.
24. Gabelt B.T., Kaufman P.L. Prostaglandin F2-increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 49:1989;389-402.
25. Gabelt B.T., Kaufman P.L. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 49:1989;389-402.
26. Galis Z.S., Muszynski M., Sukhova G.K. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 75:1994;181-189.
27. Gaton D.D., Sagara T., Lindsey J.D.et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)- isopropyl ester treatment. Arch Ophthalmol. 119:2001;1165-1170.
28. Gaton D.D., Sagara T., Lindsey J.D., Weinreb R.N. Matrix metalloproteinase-1 localization in the normal human uveoscleral outflow pathway. Invest Ophthalmol Vis Sci. 40:1999;363-369.
29. Goh Y., Oshima T., Araie M. Mechanism of intraocular pressure reduction observed after topical application of S-1033 in animals. Jpn J Ophthalmol. 38:1994;228-235.
30. Graves P.E., Pierce K.L., Bailey T.J.et al. Cloning of a receptor for prostaglandin F2 alpha from the ovine corpus luteum. Endocrinology. 136:1995;3430-3436.
31. Hayashi M., Yablonski M., Novack G. Trabecular outflow facility determined by fluorophotometry in human subjects. Exp Eye Res. 48:1989;621-625.
32. Inomata H., Bill A., Smelser G.K. Unconventional routes of aqueous humor outflow in Cynomolgus monkey (Macaca irus). Am J Ophthalmol. 73:1972;893-907.
33. Jeffrey J. Interstitial collagenases. Parks W., Mecham R. Matrix Metalloproteinases. 1998;15-42 Academic Press, San Diego, CA.
34. Jonat C., Stein B., Ponta H.et al. Positive and negative regulation of collagenase gene expression. Matrix (Suppl. 1):1992;145-155.
35. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 9:1997;240-246.
36. Kaufman P. Aqueous humor dynamics. Duane T. Clinical Ophthalmology. 1985;1-24 Harper & Row, Philadelphia.
37. Kaufman P.F. Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans. Arch Ophthalmol. 117:1999;673-674.
38. Kiriyama M., Ushikubi F., Kobayashi T.et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 122:1997;217-224.
39. Kulkarni P.S. The role of endogenous eicosanoids in rabbit-intraocular inflammation. J Ocular Pharmacol. 7:1991;227-241.
40. Lake S., Gullberg H., Wahlqvist J.et al. Cloning of the rat and human prostaglandin F2 alpha receptors and the expression of the rat prostaglandin F2 alpha receptor. FEBS Lett. 355:1994;317-325.
41. Lee P.Y., Podos S.M., Severin C. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci. 25:1984;1087-1089.
42. Lin A., Smeal T., Binetruy B.et al. Control of AP-1 activity by signal transduction cascades. Adv Second Messenger Phosphoprotein Res. 28:1993;255-260.
43. Lin C.W., Georgescu H.I., Evans C.H. The role of AP-1 in matrix metalloproteinase gene expression. Agents Actions. 39:1993;C215-C218.
44. Lindsey J.D., Kashiwagi K., Boyle D.et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 15:1996;869-875.
45. Lindsey J.D., Kashiwagi K., Kashiwagi F., Weinreb R.N. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 38:1997;2214-2223.
46. Lindsey J.D., Kashiwagi K., Kashiwagi F., Weinreb R.N. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism. implications for uveoscleral outflow Surv Ophthalmol. 41(Suppl 2):1997;S53.
47. Lindsey J.D., To H.D., Weinreb R.N. Induction of c-fos by prostaglandin F alpha in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 35:1994;242-250.
48. Lutjen-Drecoll E., Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 47:1988;761-769.
49. Lütjen-Drecoll E. Normal morphology of the uveoscleral outflow pathways. Alm A., Weinreb R. Uveoscleral Outflow. 1998;7-24 Mosby International Limited, London.
50. Matsuo T., Cynader M.S. The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle. Br J Ophthalmol. 77:1993;110-114.
51. McGetrick J.J., Wilson D.G., Dortzbach R.K.et al. A search for lymphatic drainage of the monkey orbit. Arch Ophthalmol. 107:1989;255-260.
52. Millar J.C., Kaufman P.L. PGF2 alpha/pilocarpine interactions on IOP and accommodation in monkeys. Exp Eye Res. 61:1995;677-683.
53. Miller W.L., Weeks J.R., Lauderdale J.W., Kirton K.T. Biological activities of 17-phenyl-18,19,20-trinorprostaglandins. Prostaglandins. 9:1975;9-18.
54. Nagase H., Okada Y. Proteinases and matrix degradation. Kelly W.N., Harris E.D., Ruddy S., Sledge C.B. Textbook of Rheumatology. 1997;323-341 WB Saunders Co, Philadelphia.
55. Nagase H., Suzuki K., Morodomi T.et al. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2, and 3. Matrix (Suppl. 1):1992;237-244.
56. Nagase N. Stromelysins 1 and 2. Parks W., Mecham R. Matrix Metalloproteinases. 1998;43-84 Academic Press, San Diego.
57. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors. structures, properties, and functions Physiol Rev. 79:1999;1193-1226.
58. Nilsson S.F., Samuelsson M., Bill A., Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 -1-isopropylester in the cynomolgus monkey. Exp Eye Res. 48:1989;707-716.
59. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 67:1998;179-191.
60. Ocklind A., Lake S., Wentzel P.et al. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci. 37:1996;716-726.
61. Pederson J.E., Gaasterland D.E., MacLellan H.M. Uveoscleral aqueous outflow in the rhesus monkey. importance of uveal reabsorption Invest Ophthalmol Vis Sci. 16:1977;1008-1017.
62. Pierce K.L., Bailey T.J., Hoyer P.B.et al. Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J Biol Chem. 272:1997;883-887.
63. Poyer J.F., Millar C., Kaufman P.L. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 36:1995;2461-2465.
64. Racz P., Ruzsonyi M.R., Nagy Z.T., Bito L.Z. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study. Arch Ophthalmol. 111:1993;657-661.
65. Rittig M., Lutjen-Drecoll E., Rauterberg J.et al. Type-VI collagen in the human iris and ciliary body. Cell Tissue Res. 259:1990;305-312.
66. Rosenberg G.A. Matrix metalloproteinases in brain injury. J Neurotrauma. 12:1995;833-842.
67. Sagara T., Gaton D.D., Lindsey J.D.et al. Reduction of collagen type I in the ciliary muscle of inflamed monkey eyes. Invest Ophthalmol Vis Sci. 40:1999;2568-2576.
68. Sagara T., Gaton D.D., Lindsey J.D.et al. Topical prostaglandin F2 alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 117:1999;794-801.
69. Sakamoto K., Ezashi T., Miwa K.et al. Molecular cloning and expression of a cDNA of the bovine prostaglandin F2 alpha receptor. J Biol Chem. 269:1994;3881-3886.
70. Schachtschabel U., Lindsey J.D., Weinreb R.N. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 11:2000;112-115.
71. Serle J.B., Podos S.M., Kitazawa Y., Wang R.F. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol. 42:1998;95-100.
72. Shapiro S.D., Kobayashi D.K., Pentland A.P., Welgus H.G. Induction of macrophage metalloproteinases by extracellular matrix. Evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. J Biol Chem. 268:1993;8170-8175.
73. Shaw B.R., Lindsey J.D., Weinreb R.N. Prostaglandin release in a perfused human anterior segment model. J Glaucoma. 2:1993;239-243.
74. Sjoquist B., Johansson A., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication. tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories Arzneimittel-Forschung. 49:1999;240-249.
75. Sjöquist B., Almeård B., Khalifeh V., Alm A. The bioavailability of Xalatan in the human eye. Invest Ophthalmol Vis Sci. 38(Suppl):1997;S248. [abstract].
76. Stjernschantz J., Nilsson S.F., Astin M. Vasodynamic and angiogenic effects of eicosanoids in the eye. Prog Clin Biol Res. 312:1989;155-170.
77. Stjernschantz J., Selen G., Astin M., Resul B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog Retin Eye Res. 19:2000;459-496.
78. Stjernschantz J., Selen G., Sjoquist B., Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res. 23:1995;513-518.
79. Stjernschantz J., Selén G., Ocklind A., Resul B. Effects of latanoprost and related analogues. Alm A., Weinreb R. Uveoscleral Outflow. Biology and Clinical Aspects. 1998;57-72 Mosby-Wolfe Medical Communications, London.
80. Sugimoto Y., Hasumoto K., Namba T.et al. Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem. 269:1994;1356-1360.
81. Tamm E, Rittig M, Lutjen-Drecoll E: [Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F2 alpha]. Fortschr Ophthalmol 87:623-9, 1990
82. Toris C.B., Camras C.B., Yablonski M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 100:1993;1297-1304.
83. Toris C.B., Camras C.B., Yablonski M.E., Brubaker R.F. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 41(Suppl 2):1997;S69-S75.
84. Toris C.B., Gregerson D.S., Pederson J.E. Uveoscleral outflow using different-sized fluorescent tracers in normal and inflamed eyes. Exp Eye Res. 45:1987;525-532.
85. Toris C.B., Pederson J.E. Aqueous humor dynamics in experimental iridocyclitis. X Adv Prostaglandin Thromboxane Leukot Res. 28:1987;477-481.
86. Toris C.B., Pederson J.E. Effect of intraocular pressure on uveoscleral outflow following cyclodialysis in the monkey eye. Invest Ophthalmol Vis Sci. 26:1985;1745-1749.
87. Toris C.B., Yablonski M.E., Wang Y.L., Camras C.B. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol. 127:1999;407-412.
88. Toris C.B., Yablonski M.E., Wang Y.L., Hayashi M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 61:1995;649-657.
89. Van Alphen G.W., Wilhelm P.B., Elsenfeld P.W. The effect of prostaglandins on the isolated internal muscles of the mammalian eye, including man. Doc Ophthalmol. 42:1977;397-415.
90. Wang R.F., Lee P.Y., Mittag T.W.et al. Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys. Arch Ophthalmol. 116:1998;1213-1216.
91. Wang T.H., Lindsey J.D., Weinreb R.N. Laminin subtype distribution in the human ciliary muscle. Invest Ophthalmol Vis Sci. 35:1994;3640-3648.
92. Weinreb R., Mitchell M., Alvarado J., Polansky J. Glucocorticoid regulation of eicosanoid biosynthesis in cultured human trabecular cells. Ticho U.D.R. Recent Advances in Glaucoma. 1984;213-218 Excerpta Medica - Elsevier Science Publishers B.V, Amsterdam.
93. Weinreb R.N. Enhancement of scleral macromolecular permeability with prostaglandins. Trans Am Ophthalmol Soc. 99:2001;319-343.
94. Weinreb R.N., Kashiwagi K., Kashiwagi F.et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 38:1997;2772-2780.
95. Weinreb R.N., Kim D.M., Lindsey J.D. Propagation of ciliary smooth muscle cells in vitro and effects of prostaglandin F2 alpha on calcium efflux. Invest Ophthalmol Vis Sci. 33:1992;2679-2686.
96. Weinreb R.N., Lindsey J., Luo X.X., Wang T.-H. Extracellular matrix of the human ciliary muscle. J Glaucoma. 3:1994;70-78.
97. Weinreb R.N., Mitchell M.D. Prostaglandin production by cultured cynomolgus monkey trabecular meshwork cells. Prostaglandins Leukot Essent Fatty Acids. 36:1989;97-100.
98. Weinreb R.N., Mitchell M.D., Polansky J.R. Prostaglandin production by human trabecular cells. in vitro inhibition by dexamethasone Invest Ophthalmol Vis Sci. 24:1983;1541-1545.
99. Woessner J.F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
100. Wood R.L., Koseki T., Kelly D.E. Uveoscleral permeability to intracamerally infused ferritin in eyes of rabbits and monkeys. Cell Tissue Res. 270:1992;559-567.
101. Woodward D.F., Lawrence R.A., Fairbairn C.E.et al. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies. J Lipid Mediat. 6:1993;545-553.
102. Ziai N., Dolan J.W., Kacere R.D., Brubaker R.F. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 111:1993;1351-1358.